SCHEMBL23340697

SCHEMBL23340697

Cc1ccc(-c2cc(Cn3c(Cl)nc4c3C(=O)N(C)COCN4C)no2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ NPC1 O15118 6/20 0.39
▸ RAB9A P51151 6/20 0.39
▸ EPHX2 P34913 2/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ ADORA2B P29275 3/20 0.35
▸ ADORA2A P29274 2/20 0.35
▸ ADORA1 P30542 2/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ SMN1; SMN2 Q16637 5/20 0.35
▸ TP53 P04637 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ F10 P00742 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NOTUM Q6P988 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23340460 0.82 POLB (0.39) POLBNPC1RAB9AEPHX2ALDH1A1
SCHEMBL23340495 0.76 DRD2 (0.32) SMN1; SMN2NOTUM
SCHEMBL23340327 0.74 CA12 (0.45) KMT2APOLBMAPTTDP1NPC1
SCHEMBL23297795 0.73 HTT (0.54) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL23340326 0.72 F10 (0.41) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL23340547 0.72 RAB9A (0.50) MEN1KMT2APOLBMAPTNPC1
SCHEMBL23340548 0.71 RAB9A (0.40) MEN1KMT2APOLBMAPTNPC1
SCHEMBL23340490 0.71 TSHR (0.43) MEN1KMT2APOLBMAPTNPC1
SCHEMBL23340492 0.70 ALDH1A1 (0.43) KMT2APOLBMAPTRAB9AALDH1A1
SCHEMBL23340635 0.69 PTK2 (0.43) MAPTRAB9AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210128566-A1 NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128566-A1 NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE ADORA2A, HPRT1, PNP MEN1 1791/4885KMT2A 2701/4885POLB 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback